Introduction
ConcertAI is a Cambridge, Massachusetts company founded in 2017 that builds agentic artificial intelligence and real-world data solutions for oncology and complex disease research. Jeff Elton, Ph.D., served as founding chief executive officer from the company’s inception and, as of ConcertAI’s leadership page reviewed in July 2026, holds the title of Vice Chairman while Eron Kelly serves as chief executive officer following a transition announced May 1, 2025. ConcertAI’s portfolio spans life-sciences SaaS, clinicogenomic data services, and provider-facing tools including the CancerLinQ initiative.
For readers tracking applied AI in healthcare analytics, ConcertAI represents a mature attempt to embed predictive and agentic AI directly into clinical trial design, feasibility, site selection, and commercial patient-journey workflows — not as experimental dashboards but as enterprise software tied to multi-year pharma partnerships.
What the company does
ConcertAI provides oncology-focused AI SaaS built on its CARAai platform, combining real-world and proprietary datasets with agentic workflows that automate literature review, protocol design, competitive trial analysis, feasibility assessment, site selection, and patient matching. Its Precision Suite and related products target life-sciences functions from clinical development through commercial operations, while CancerLinQ and TeraRecon extend capabilities into oncology provider quality programs and radiology decision augmentation respectively.
The company’s February 2026 launch of Accelerated Clinical Trials (ACT) formalized an enterprise agentic AI layer aimed at shortening end-to-end trial timelines by automating critical trial activities with predictive intelligence — a product direction ConcertAI framed at SCOPE 2026 as reducing overall trial duration by ten to twenty months in modeled scenarios.
ConcertAI’s multi-modal data assets — spanning claims, molecular diagnostics, imaging context, and provider-reported oncology records — are structured for AI consumption rather than ad hoc analyst queries. Pharmaceutical teams want repeatable SaaS modules with audit trails, not bespoke consulting projects rebuilt for every brand launch. Provider-facing CancerLinQ enhancements similarly assume oncologists will not leave their EHR to consult standalone trial search portals.
Who it serves
ConcertAI sells primarily to top-tier life-sciences organizations, contract research organizations, and oncology provider networks. Its public materials reference partnerships with a large share of leading biomedical innovators and more than two thousand healthcare providers and medical societies. Commercial teams use Cadence Suite-style patient-journey analytics; clinical development teams use ACT and Translational360 molecular data products; oncologists interact with CancerLinQ trial-matching enhancements at the point of care.
Company background
ConcertAI was founded in 2017 in Cambridge by Jeff Elton and Romesh Wadhwani, Ph.D., who remains Executive Chairman. Under Elton’s tenure as founding CEO, ConcertAI acquired TeraRecon imaging technology and expanded the CancerLinQ oncology clinic network, establishing collaborations with NVIDIA and major molecular diagnostics companies. On May 1, 2025, ConcertAI announced that Eron Kelly would succeed Elton as CEO while Elton moved to Vice Chairman, continuing as a strategist and industry voice for the company.
Product and AI capabilities
ConcertAI’s AI stack emphasizes agentic workflows — purpose-built assistants and agents trained for life-sciences use cases rather than general-purpose models adapted post hoc. ACT deploys these agents across trial design and operations, integrating real-world data with reasoning models for feasibility and patient matching. CancerLinQ enhancements unveiled for ASCO 2026 apply clinically intelligent AI to structured and unstructured oncology records for trial eligibility matching, which ConcertAI claims can screen eligible patients significantly faster than manual methods when integrated into existing workflows.
The distinction matters for buyers: ConcertAI markets AI that executes multi-step trial and commercial workflows with auditability, not single-model chat interfaces layered onto static dashboards.
Key developments
2017: ConcertAI founded in Cambridge, Massachusetts. May 1, 2025: Leadership transition — Eron Kelly appointed CEO; Jeff Elton became Vice Chairman (announced agreement, not a third-party report). February 2, 2026: ConcertAI launched Accelerated Clinical Trials (ACT) at SCOPE 2026, per the company’s official press release cited in this profile.
Why it matters
ConcertAI matters because oncology R&D and provider analytics are converging on the same underlying need: faster, auditable intelligence across fragmented clinical and molecular data. ACT is a concrete 2026 product milestone showing agentic AI moving from roadmap language into named enterprise trial software. The May 2025 CEO transition also signals ConcertAI’s evolution from founder-led startup to scaled SaaS vendor — a pattern Brel readers will recognize across mature healthcare AI companies entering their second growth phase.
Pharmaceutical procurement teams increasingly bundle real-world data subscriptions with AI workflow modules; ConcertAI’s combined TeraRecon, CancerLinQ, and CARAai footprint lets it sell that bundle where standalone analytics vendors cannot. Hospital oncology leaders evaluating trial-matching tools should ask whether vendor AI runs inside their existing CancerLinQ or EHR context — integration depth often determines adoption more than standalone model accuracy claims.
Sector context
ConcertAI belongs in Brel’s AI in healthcare coverage under healthcare analytics and oncology real-world evidence, related to precision medicine platforms such as Tempus AI and digital pathology vendors whose tissue data feeds broader clinicogenomic strategies. Readers comparing clinical AI vendors should distinguish analytics-and-trial orchestration companies like ConcertAI from diagnostic imaging AI point solutions where regulatory pathways and buyers differ materially.
Sources and references
ConcertAI ACT launch press release (February 2, 2026) and About Us leadership page.
- ConcertAI — Accelerated Clinical Trials launch (concertai.com, February 2, 2026)
- ConcertAI — About Us / leadership (concertai.com)
Reviewed July 10, 2026. Jeff Elton is founding CEO, now Vice Chairman; Eron Kelly is CEO.